Samsung Bioepis to Present P-III Exploratory Analyses Results of Aybintio (bevacizumab, biosimilar) at ESMO 2020

 Samsung Bioepis to Present P-III Exploratory Analyses Results of Aybintio (bevacizumab, biosimilar) at ESMO 2020

Samsung Bioepis to Present P-III Exploratory Analyses Results of Aybintio (bevacizumab, biosimilar) at ESMO 2020

Shots:

  • The exploratory analyses of the P-III study evaluate the equivalent efficacy of Aybintio vs reference bevacizumab in combination with paclitaxel & carboplatin, q3w up to 6 cycles followed by Aybintio or reference bevacizumab as maintenance monothx. in 665 patients with metastatic/recurrent nsq. NSCLC
  • Results: previous analysis demonstrate ORR in PPS (50.1% vs 44.8%); expanded analysis showed the risk difference in best ORR by 11 & 17wks. (2.2% vs 2.4%); mean of maximum % change from baseline in tumor burden @24wks. (-27.8% vs -27.3%)
  • Aybintio is a biosimilar referencing Avastin and has received EC’s approval in Aug’2020 for mCRC, mBC, NSCLC, mRCC, epithelial ovarian, fallopian tube, primary peritoneal cancer and cervical cancer

Click here ­to­ read full press release/ article | Ref: Samsung Bioepis | Image: The Investor

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post